Table 1.

Anti-rhIDUA antibody titer measurements in synovial fluid demonstrated near-zero titers in fluid from all joints at baseline. At the end of the study, the rhIDUA-treated joints demonstrated the highest anti-rhIDUA antibody titers, while the saline-treated joints had elevated anti-rhIDUA antibody titers, but below circulating serum titer levels. Of note, Sph, the animal treated with prednisone prior to study initiation, had the lowest saline-treated titer level and the second lowest rhIDUA-treated titer level.

Synovial Fluid		OD Units/ul
		Baseline	Post-treatment
Oks	Saline-treated	0.180	98.8
Spi	Saline-treated	0	229
Spo	Saline-treated	0	167
Sph	Saline-treated	0.140	21.1
Mean ± SD		0.08 ± 0.09	129 ± 89
Oks	rhIDUA-treated	0	613
Spi	rhIDUA-treated	2.70	1500
Spo	rhIDUA-treated	0.540	1280
Sph	rhIDUA-treated	0	708
Mean ± SD		0.81 ± 1.29	1025 ± 432